Breakthrough Study Reveals How a Metabolic Pathway Could Reverse Alzheimer's Memory Loss
Breakthrough Study Reveals How a Metabolic Pathway Could Reverse Alzheimer's Memory Loss
Breakthrough Study Reveals How a Metabolic Pathway Could Reverse Alzheimer's Memory Loss
A new study has uncovered a molecular pathway that could help restore cognitive function in Alzheimer's disease. Researchers found that boosting a specific metabolic process improves memory and synaptic health in mice with Alzheimer's-like symptoms. The findings, published in Experimental & Molecular Medicine, suggest potential avenues for human treatments.
The study centres on an enzyme called HMGCS2, which produces β-hydroxybutyrate (β-OHB)—a molecule that acts as both an energy source for neurons and a signalling compound. In Alzheimer's, this metabolic pathway weakens, reducing β-OHB levels and disrupting a key epigenetic marker called H3K9bhb. The loss of this marker contributes to synaptic damage and cognitive decline.
When scientists increased HMGCS2 activity in mice, β-OHB production rose, triggering changes in chromatin structure through H3K9bhb. This modification enhanced the expression of genes critical for synaptic function and neuroprotection. Treated mice showed significant cognitive improvements, demonstrating the pathway's potential.
The team also observed similar effects in human neurons when β-OHB levels were raised. This consistency strengthens the case for targeting HMGCS2 in Alzheimer's therapies. Possible approaches include pharmacological agents to boost the enzyme or gene therapy to increase its expression in the brain.
Researchers propose that measuring β-OHB or H3K9bhb levels in blood or cerebrospinal fluid could help track disease progression or gauge responses to metabolic treatments. However, no public records currently detail the number of clinical trials exploring β-OHB elevation in Alzheimer's patients.
The discovery highlights a direct link between metabolism and epigenetic regulation in Alzheimer's disease. By restoring HMGCS2 activity and β-OHB levels, cognitive function may be preserved or improved. Further research will determine whether these findings translate into effective human therapies.